John Rossi, MS, CERo Therapeutics, San Francisco, CA, provides an overview of novel chimeric engulfment receptor (CER) T cells which consist of an autologous T cell engineered to express a CER derived from myeloid lineage cells, which can remove diseased or dying cells. CER T-cells behave like chimeric antigen receptor (CAR) T-cells but can enhance antigen presentation of T cells, mediating tumor clearance and inducing a secondary immune response. The technology has the potential to be used in multiple indications including leukemia, lymphoma and solid tumors. This interview took place at the 2021 CAR-TCR Summit 2021.
John Rossi is an employee and equity stakeholder of CERo Therapeutics.